A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion

Stress cardiomyopathy is a transient left ventricular dysfunction caused by physiologic or pathologic stressors. Anaphylaxis is a hypersensitivity disorder that can lead to a rapid life-threatening respiratory collapse. It happens due to exposure to allergens including medications. During anaphylaxi...

Full description

Bibliographic Details
Main Authors:	Harjinder Singh MD, Omair Ahmed MD, Erin Allen ACS, Hussein Othman MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-11-01
Series:	Journal of Investigative Medicine High Impact Case Reports
Online Access:	https://doi.org/10.1177/23247096231209554

Similar Items

Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags
by: Helen Linxweiler, et al.
Published: (2024-10-01)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
by: Hiraku Kokubu, et al.
Published: (2023-05-01)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
by: Rui Wan, et al.
Published: (2023-06-01)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
by: Md Sazzad Hassan, et al.
Published: (2023-07-01)

Macular Cystoid Edema Induced by Nab-Paclitaxel
by: Sara Alves Pereira, et al.
Published: (2022-04-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
by: Shuling Chen, et al.
Published: (2023-03-01)

Nab-Paclitaxel for Relapsed AIDS-Related Kaposi Sarcoma -A Case Report
by: Yu L, et al.
Published: (2024-04-01)

A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
by: Shetal A. Patel, et al.
Published: (2021-08-01)

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study
by: Swapna Kochuveettil, et al.
Published: (2024-10-01)

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
by: Hiromi Okuyama, et al.
Published: (2018-10-01)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
by: Jiahui Shen, et al.
Published: (2023-02-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

Bilateral macular edema secondary to nab-paclitaxel therapy for breast cancer
by: Zi-Yi Zhou, et al.
Published: (2024-10-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
by: Jingjing Zhang, et al.
Published: (2023-03-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)

A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study
by: Chen Chang MD, et al.
Published: (2022-11-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01)

A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
by: Kellie L. Bodeker, et al.
Published: (2024-11-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
by: Katsurada N, et al.
Published: (2020-02-01)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
by: Javier Martin-Broto, et al.
Published: (2022-10-01)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialResearch in context
by: Tanios Bekaii-Saab, et al.
Published: (2023-04-01)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
by: Cheng-Ke Xie, et al.
Published: (2024-09-01)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
by: Guillaume Joe Pegna, et al.
Published: (2023-02-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases
by: Lisa D. Volk, et al.
Published: (2011-04-01)

Delayed Presentation of a Post-infarction Ventricular Septal Rupture
by: Omair Ahmed MD, et al.
Published: (2024-06-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
by: I. A. Pokataev, et al.
Published: (2019-12-01)

Nab-Paclitaxel Based Chemotherapy in the Treatment of Advanced Epithelioid Hemangioendothelioma: A Single-Institution Experience
by: Liu X, et al.
Published: (2025-02-01)

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
by: Md. Hafiz Uddin, et al.
Published: (2023-12-01)

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
by: Sirui Tan, et al.
Published: (2022-11-01)

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
by: Morgensztern, D, et al.
Published: (2017)

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
by: Margaret M. Byrne, et al.
Published: (2024-07-01)

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy
by: Ziyi Yang, et al.
Published: (2022-08-01)

Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis
by: Wenjing Hao, et al.
Published: (2023-07-01)

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
by: Rei Tsutsumi, et al.
Published: (2022-07-01)